The Milan criteria are still considered the gold standard for patient selection criteria for liver transplantation in patients with hepatocellular carcinoma. However, those criteria may be too strict and thus exclude a significant number of patients who could benefit from liver transplantation. Based on this notion, many expanded selection criteria have been suggested. In Asian countries, where there is a serious shortage of deceased donor organs, living donor liver transplantation accounts for the majority of all liver transplant cases. Because living donor liver transplantation is not controlled by the public allocation system, the indications for living donor liver transplantation can be expanded. In Korea, living donor liver transplantation depends entirely on the discretion of the transplant team and the donor. Hence, Korean transplant centers have had a reasonable amount of experience with liver transplantation for advanced hepatocellular carcinoma. Experiences in Korea show that serum alpha-fetoprotein level, des-gamma-carboxy prothrombin level and positron emission tomography are very useful biomarkers in predicting tumor recurrence after transplantation. Tumors that show favorable levels of these biomarkers might not recur after transplantation despite being morphologically advanced. In addition, combination therapy with mammalian target of rapamycin inhibitors and sorafenib may improve survival even after tumor recurrence. Therefore, in Korea, living donor liver transplantation is considered even for cases of far advanced hepatocellular carcinoma if a recipient has no other effective treatment options and a well-informed donor wishes to willingly participate.
Introduction
Liver transplantation (LT) has been considered one of the best treatment modalities for early stage hepatocellular carcinoma (HCC) since the Milan criteria were suggested by Mazzaferro et al. The Milan criteria are defined as a single tumor 5 cm or less in size, or three or fewer tumors 3 cm or less in size without major vessel invasion or extrahepatic disease (1) . Patients with HCCs fulfilling the Milan criteria had a 75% overall survival rate and an 83% recurrence-free survival rate at 4 years after LT (1) . The Milan criteria justified the use of LT for HCC by improving the long-term results to levels comparable to those of LT for non-malignant conditions. The Milan criteria were designed for deceased donor LT (DDLT), where the donor graft is a public resource. In most Asian countries, including Korea, however, living donor LT (LDLT) accounts for the majority of LT cases (2) because of a serious scarcity of deceased donor grafts. A living donor graft is dedicated to only one potential recipient, and is thus not allocated by the public organ sharing system (2, 3) . Therefore, a lower estimated survival rate after LT could be acceptable in LDLT compared with DDLT (4, 5) . Moreover, in Korea, LT for advanced HCC is not restricted by the Korean Network for Organ Sharing and is also not excluded by health insurance coverage. It completely depends on the discretion of the transplant team and the living donor. Hence, Korean LT centers have quite a few experiences with LT for advanced HCC. This article reviewed the Korean experience with LT for HCC and assessed the possibility of further expansion of LT criteria for HCC.
Expansion of the Milan criteria
Although the Milan criteria are still the most widely accepted criteria for LT for HCC, there has been a debate as to whether the restrictions imposed by those criteria are excessive (6) . With strict adherence to the Milan criteria, only 6% of patients with HCC would be eligible for LT (7, 8) , while studies done worldwide show that many patients with HCC that has advanced beyond the Milan criteria actually have good survival rates. Therefore, the Milan criteria may exclude a significant proportion of the patients who could benefit from LT. Thus, there have been many attempts to expand the patient selection criteria for LT with acceptable post-transplant survival rates (Table 1) (2, (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Yao et al. (19) of the University of California San Francisco (UCSF) suggested expanded criteria for LT for HCC in 2001; the criteria that they proposed consist of one tumor 6.5 cm or less in diameter, or two to three tumors, each 4.5 cm or less in diameter, with a total diameter of 8 cm or less. In a prospective validation based on pre-transplant imaging, they reported that the 5-year recurrence rate of patients treated with the USCF criteria was only 9%, whereas the survival rate without recurrence was 81% (9) . Thus, they successfully expanded the criteria without increasing HCC recurrence rate. However, because a very small portion of patients with HCC beyond the Milan criteria (~3%) are candidates for LT under the USCF criteria (20) , those criteria have not yet been globally adopted as a replacement for the Milan criteria (5).
Mazzaferro et al. (10) proposed a new set of criteria, known as the 'Up-to-seven' criteria: tumors with seven as the sum of the size of the largest tumor (in cm) and the number of tumors. According to their study, patients who meet the Up-to-seven criteria had a 5-year overall survival rate of 71% without microvascular invasion, which was comparable to the results based on the Milan criteria. However, the rate was only 47% with microvascular invasion (10) . Unfortunately, it is difficult to confirm the presence of microvascular invasion before LT.
Toso et al. (13) suggested total tumor volume as a predictor of post-transplant recurrence instead of size and number, and subsequently developed a new composite of criteria defined as tumors with total liver volume of 115 cm 3 or less and a serum alpha-fetoprotein (AFP) level of 400 ng/ml or less (21) . In their recent prospective validation, patients beyond the Milan criteria but within the new criteria had an acceptable recurrence rate (9%) and overall survival rate (75% at 4 years after LT) (18) . However, this approach may be limited because the total tumor volume was derived from tumor diameter rather than more precise measurements (5).
More recently, some centers have used other parameters reflecting the biological behavior of tumors other than the conventional parameters such as tumor size and number. The Hanzhou and Toronto group added the results of tumor biopsy to their selection criteria (14, 15) . They suggested selective exclusion of patients with poorly differentiated tumors seen on pre-transplant biopsy, while they extended the upper permissible limit of the size and number of tumors. However, preoperative needle biopsy can increase tumor seeding and post-transplant recurrence as well as cause bleeding in cirrhotic patients (22, 23) . Hence, the use of pre-transplant pathologic features for patient selection is a matter of debate.
Non-invasive biomarkers have been studied as predictors of post-LT recurrence include tumor markers, fluorine-18-flurodeoxyglucose (18 F-FDG) positron emission tomography (PET) and systemic inflammatory markers (24) . Among them, AFP is the most well-known risk factor for HCC recurrence after LT. As mentioned earlier, some centers currently use AFP in patient selection for LT (14, 18) . Some Japanese centers use another tumor marker, des-gamma-carboxy prothrombin (DCP), also known as protein induced by vitamin K absence or antagonist II. Preoperative serum DCP level was reported as a possible indicator of microvascular invasion in HCC (25) (26) (27) . The correlation between high DCP levels and HCC recurrence after LT has been suggested by recent studies done in Japan (28) (29) (30) . Hence, the Kyoto and Kyushu groups have already updated their selection criteria to include pre-transplant DCP level. The Kyoto group proposed expanded criteria including serum DCP level, and increased the upper limit of the number of tumors to 10 (17) . These criteria are defined as 10 or fewer tumors 5 cm or less in diameter and serum DCP levels of 400 mAU/ml or less. They reported that the 5-year overall survival rate and diseasefree probability for patients within their criteria were 82% and 93%, respectively (17) . The Kyushu group removed the limitation on the number of tumors in their expanded criteria. All HCCs with a diameter <5 cm or with a DCP level <300 mAU/ml were included in their selection criteria (16) . The 5-year post-transplant recurrence-free rates were 80% using the Kyushu criteria, which are similar to the original results of the Milan group. They claimed that the Kyushu criteria are the most powerful predictive criteria for HCC recurrence when compared with other expanded criteria and are useful in eliminating LT candidates at a very high risk of HCC recurrence (16) .
Several other expanded criteria have been proposed to date. Although the Milan criteria are still recognized as the gold standard worldwide, it is generally agreed that the Milan criteria may be overly restrictive and thus exclude a significant number of HCC patients who could benefit from LT. Morphological parameters of tumors such as size and number may be the most significant predictors of HCC recurrence after LT, and have been used as a selection tool for LT candidates with HCC for 20 years since the extraordinary achievement of the Milan group. However, it is increasingly evident that these morphological parameters alone are not good enough to differentiate between tumors with favorable outcomes and those that disseminate early (5) . Therefore, the expansion of the criteria using those morphological parameters seems to be at the breaking point. Clearly, some tumors do not recur after LT even in cases of morphologically advanced HCC (31) . Various biomarkers have recently been investigated as predictors of HCC recurrence, and the significance of such biomarkers continues to become clearer as practitioners navigate the clinical decisions regarding LT for HCC (4). The criteria for LT for HCC should be expanded by combining morphological and biological parameters. Some recent studies have shown that the upper limits of the size and number of transplantable HCCs can be expanded by using tumor markers such as AFP or DCP.
Expanded Korean criteria for LT for HCC
LDLT is an important alternative to DDLT in Asia, where there is a serious shortage of deceased donor organs for a variety of social and cultural reasons (32) . LDLT accounts for~70% of all LT cases in Korea, although the proportion of DDLT has been on the rise. Korean LT centers apply and implement relatively liberal criteria for LT for HCC because of the distinct situation concerning LDLT in Korea (Table 2 ) (33-36). The Asan criteria were proposed by Lee et al. (33) . Six or fewer tumors with a maximum diameter of 5 cm or less were permitted as long as there was neither gross vascular invasion nor extrahepatic disease. The 5-year overall and recurrence-free survival rates for patients within the Asan criteria were 76% and 85%, respectively, which were comparable to those for patients within the Milan or UCSF criteria (33) . Choi et al. (34) from the Catholic Medical Center further extended the eligibility criteria for LT to up to seven tumors with a maximum diameter of 7 cm or less. In their series, the 5-year overall and recurrence-free survival rates were 72% and 87%, respectively (34) . Both criteria use only conventional morphological parameters, just as do the Milan and USCF criteria. In addition, those criteria seem to nearly reach the upper limit of the size and number of transplantable tumors. Thus, some other centers use biologic markers to further expand the criteria. Kim et al. (35) at the Samsung Medical Center (SMC) used AFP to expand the selection criteria. They suggested that LDLT could reasonably be performed for HCC patients with no more than seven tumors 6 cm or less in diameter and with serum AFP levels of 1000 ng/ml or less (35) . The 5-year recurrence-free rates were 84% within the Samsung criteria, which were similar to the original result (83% at 4 years after LT) of the Milan group (1, 35) .
Recently, Lee et al. (36) from the National Cancer Center Korea (NCCK) proposed new expanded criteria using total tumor size and 18 F-FDG PET. The significance of PET in predicting HCC recurrence after LT was first suggested by Yang et al. from Seoul National University Hospital (SNUH) in 1996 (37) and has subsequently been validated in many studies (38) (39) (40) (41) (42) (43) (44) . Hot FDG uptake on PET imaging was related to high AFP, poor differentiation and vascular invasion (37, 45, 46) . In particular, patients beyond the Milan criteria but with negative PET status were shown to have good overall and recurrence-free survival rates comparable to those within the Milan criteria (41, 43) . The NCCK criteria were defined as tumors with a total tumor size of 10 cm or less and negative PET status. In their study, the 5-year overall and disease-free survival rates of 164 patients within the NCCK criteria were 85.2% and 84.0%, respectively (36) . The NCCK criteria increased the number of candidates suitable to LT by 24% compared with the Milan criteria, while the results of the NCCK were not inferior to those of the Milan criteria (36) .
However, PET positivity has not yet been clearly defined. According to the NCCK criteria, the PET positivity was assessed by experienced nuclear medicine physicians who checked that the maximal standard uptake value of a tumor (T max ) was higher than that of surrounding noncancerous liver tissue (L max ) (T max /L max > 1.0) (36) . On the other hand, Lee et al. (38) reported that a T max /L max value >1.15 was the most effective predictor of HCC recurrence after LT. In addition, Hong et al. (44) suggested that the cutoff value of T max /L max should be 1.10 using receiver operating characteristic curve analysis. This uncertainty PET positivity is an obstacle to using PET in the patient selection process for LT.
Most Korean criteria for LT for HCC have been established on the basis of LDLT situation. There is no consensus on the DDLT criteria for HCC in Korea. Therefore, the patient selection for DDLT for HCC completely depends on the policy of each center. Nonetheless, the deceased donor allocation system of Korea does not have any restriction for patients with advanced HCC. This may be an important issue to be addressed. Liberal DDLT for advanced HCC may be possible under the present system of Korea. This would not only impair overall DDLT outcomes, but would also limit the access to DDLT of patients with non-malignant disease Table 2 . The recurrence of HCC was considered as an event, but patient death was censored.
because the incidence rate of HCC is high in Korea (8) . Therefore, the consensus on the criteria for DDLT for HCC should be established as soon as possible because DDLT is increasing.
Korean experiences for advanced HCC
There is no legal restriction and no penalty of health insurance for LT for advanced HCC in Korea. If there are no effective treatment options other than LT, patients are expected to benefit from LT, and the expected survival and donor risk are fully understood by both the recipient and the donor, LDLT is not contraindicated even for far advanced HCC (31) . Thus, many Korean LT centers occasionally perform LT for far advanced HCC even over the expanded selection criteria of their own and the only absolute contraindication for LDLT at our center is extrahepatic metastasis (31) .
It is generally agreed that HCC patients with macrovascular invasion should be excluded from LT. However, we found that patients with portal vein tumor thrombus (PVTT) but with a pretransplant serum AFP level of 200 ng/ml or less had acceptable overall and disease-free survival rates after LT. In our experience, although all patients with PVTT and serum AFP level >200 ng/ml had HCC recurrence within 2 years after LT, the 3-year overall and disease-free survival rates of patients with PVTT but AFP level ≤200 ng/ml were 87.5% and 65.5%, respectively (31) . Therefore, patients with advanced HCC may still have a good chance of survival if the biology of the tumor is favorable.
An unpublished Korean multicenter study shows similar results. Six hundred eighty-eight patients beyond the Milan criteria underwent LT in eight Korean LT centers between January 2000 and June 2013. The 5-year overall and disease-free survival rates of all patients beyond the Milan criteria were 60.4% and 55.1%, respectively. Of all patients, 169 patients underwent LT for far advanced HCC (HCCs with a maximum diameter >10 cm, >10 tumors or macrovascular invasion). The 5-year overall and disease-free survival rates of those patients were 28.7% and 24.8%, respectively. However, patients with a sum of AFP and DCP <300 had acceptable disease-free survival despite far advanced HCC (53.4% at 5 years after LT). In addition, those patients accounted for 31% of all patients with far advanced HCC. These observations suggest that a significant number of patients who could benefit from LT can be identified using biomarkers such as AFP and DCP even when HCC is in an advanced stage.
Interestingly, a recent Korean study developed a new scoring system to predict post-LT recurrence for patients with advanced HCC using square-root values of AFP and DCP. Data from 92 patients who consecutively underwent LDLT for HCC beyond the Milan criteria in SNUH between September 2001 and January 2013 were analyzed. The risk score, termed the MoRAL score, was calculated as 11 × √DCP + 2 × √AFP (47). This score was validated in 113 patients beyond the Milan criteria who underwent LDLT in NCCK and SMC between June 2003 and July 2013. According to their study, at a cutoff of 314.8 (75th percentile), a low MoRAL score was associated with significantly longer recurrence-free and overall survival rates in the cohort with HCC beyond the Milan criteria. The 5-year recurrence-free and overall survival rates of patients beyond the Milan criteria but with a low MoRAL score were as high as 66.3% and 82.6%, respectively, which were superior to those of patients within the Milan criteria but with a high MoRAL score. Moreover, patients with a low MoRAL score had a significantly lower risk of tumor recurrence regardless of the presence of portal vein invasion (47).
Hong et al. (44) suggested the significance of AFP and 18 F-FDG PET in predicting HCC recurrence after LT. They investigated data from 123 patients who underwent LDLT between January 2003 and December 2009. According to their study, positive PET status defined as T max /L max >1.10 and high serum AFP level ≥200 ng/ml were independently significant pre-transplant prognostic factors in multivariate analysis, while tumor number and size were not significant. The hazard ratios (HRs) of positive 18 F-FDG PET (T max /L max >1.10) and high serum AFP (≥200 ng/ml) for tumor recurrence after LT were 9.766 (95% CI: 3.557-26.816) and 6.234 (95% CI: 2.643-14.707), respectively. In addition, the combination of positive PET and high serum AFP yielded a very high HR of 29.069 (95% CI: 8.797-96.053) compared with the double-negative group, while the HR using the Milan criteria was only 1.351 (95% CI: 0.500-3.652) (44) . When risk stratification analysis was done with patients divided into three groups according to two biologic factors, i.e. a high-risk group (AFP ≥200 ng/ml, PET (+)), an intermediate-risk group (AFP ≥200 ng/ml, PET (−) or AFP <200 ng/ml, PET (+)) and a low-risk group (AFP <200 ng/ml, PET (−)), the 5-year disease-free survival rate of the high-risk group was as low as 8.3% for all patients and also only 16.7% even for patients who met the Milan criteria. On the other hand, the 5-year disease-free survival rate of the low-risk group was 93.7% for all patients and 100% even for those beyond the Milan criteria (44) . The combination of serum AFP level and 18 F-FDG PET status were much more closely correlated with tumor recurrence than were the Milan criteria. Therefore, such biomarkers may play a significant role as patient selection tools for LT for HCC even without taking into account morphological parameters.
Generally, PVTT or extrahepatic spread are considered to be contraindicators for LT. Nevertheless, experience with successful LT after multidisciplinary treatment for such cases has been reported by a group from the Yonsei University Severance Hospital of Korea. and cisplatin (60 mg/m 2 over 2 hours on day 2) were infused every 4 weeks for 3-12 months, adjusting for tumor response. LDLTs were performed in eight consecutive patients who achieved successful down-staging of HCC between December 2011 and September 2012. According to their report, the 1-year disease-free survival rate was 87.5%, and three patients had tumor recurrence during the follow-up period (48) . Although long-term results are not available, considering that HCC with PVTT usually carries a 1-year survival rate <10%, LDLT may be a therapeutic option even for patients with initially advanced HCC with PVTT if the tumors are down-staged after intensive multidisciplinary treatment (49). Yoo et al. (50) , from the same group, reported an experience of LDLT for HCC accompanying lymph node metastasis before treatment. A 52-year-old man was initially diagnosed with a huge HCC of 14.5 cm and a metastatic lymph node in the right cardiophrenic space by computed tomography and 18 F-FDG-PET. He underwent combination treatment with CCRT followed by HAIC and sorafenib for 1 year, and then additional sorafenib monotherapy for 2 years. The size of the tumor decreased to 6.4 cm and the patient's serum AFP level dropped from 3690 ng/ml into the normal range. In addition, a remarkable decrease in FDG uptake in the primary tumor was identified without visible metastasis on PET. However, he finally underwent LDLT due to decompensated liver function. Posttransplant pathological examination showed only totally necrotic nodule and fibrous capsule formation in the liver. He had no recurrence during 11 months after LT (50) . Experiences like this one indicate that the decision to perform LT should not be made based on the initial stage of HCC. Patients with advanced HCC even accompanying PVTT or extrahepatic spread could benefit from LT if morphological and biological responses to intensive multidisciplinary treatments are favorable.
How far we can go in LDLT for HCC
In DDLT, liver grafts are public resources that can be supplied to only a small group of patients who need LT because of a shortage of donor organs. A too-liberal expansion of the criteria for HCC would not only worsen the overall outcomes of LT, but also limit the access to LT of patients with other liver diseases, particularly in areas with a high incidence of HCC (8) . Thus, an expansion of the LT criteria for HCC should be balanced with the survival of patients with other etiologies. However, the landscape of LDLT differs from that of DDLT. Liver grafts for LDLT are not publicly allocated because they are dedicated to only one potential recipient based on the close relationship between the donor and the recipient. Therefore, the overall chance of survival of the recipient and the wishes of the donor as well as the risk of recurrence after LT should be considered in the setting of LDLT (4) .
Frequently, although a potential donor is fully informed of the low possibility of survival of the patient and the potential risks of surgery, he or she earnestly requests LDLT when a patient has few better treatment options (31) . In addition, it is not clear whether or not a physician has the right to deny a request for LDLT when a donor wishes to provide the only potential chance for curative treatment to his or her family member (5) . Hence, many patients with advanced HCC undergo LDLT in Korea (31) .
Nonetheless, expansion of the criteria for LT should be restricted even in LDLT because LDLT inevitably carries significant risks of donor morbidity and mortality. The risks of death and life-threatening complications to living donors have been reported to be as high as 0.3% and 2%, respectively (51) (52) (53) . There is no clear minimal estimated survival rate that can overcome the risk to a donor in LDLT, and this is a critical question that must be addressed (4). The acceptable target outcomes may vary from 60% or even as low as 50% survival at 5 years post-LT to somewhere closer to that achievable under the Milan criteria (54) . The issue certainly depends on maintaining an appropriate balance between recipient benefit and donor risk. Although no consensus has been developed, a long-term expected survival of~50% is generally considered acceptable in LDLT in Korea (4, 31, 55) .
HCC recurrence after LT is considered to be a disaster. The condition rapidly progresses when a patient is in an immunocompromised state and leads to death in most cases even when aggressive and combined therapeutic approaches are applied (56, 57) . This is one reason why physicians hesitate to perform LT for advanced HCC. However, the recent introduction of mammalian target of rapamycin (mTOR) inhibitors and targeted agents such as sorafenib could relieve some pressure regarding post-LT recurrence when expanding the criteria for LT. mTOR inhibitors are known to be antineoplastic and may reduce HCC recurrence rates. Some studies have suggested that sirolimus-based immunosuppression may be associated with delayed tumor recurrence compared with tacrolimus-based regimens (58, 59) . In addition, switching to an mTOR inhibitor after development of recurrence produced encouraging results (60, 61) . In patients with advanced HCC and compensated liver cirrhosis, sorafenib has been shown to improve survival by~3 months (62) . Several groups have also reported survival benefits of sorafenib treatment in patients with HCC recurrence after LT, in most cases in combination with mTOR inhibitor-based immunosuppression (61, (63) (64) (65) . In addition, a few cases of complete remission after sorafenib treatment have been reported (66) (67) (68) .
Hong et al. (65) from Pusan National University Yangsan Hospital of Korea reported their experiences with sorafenib treatment for recurrent HCC after LT in 2015. Three of four evaluated patients stabilized after sorafenib treatment, although one patient had progressive disease even after sorafenib treatment and eventually died at 14 months after recurrence. The three patients who responded to sorafenib remained in a stable disease state for 5-38 months and were alive for 21-38 months after recurrence. One year later, Lee et al. (68) , working at the same center, reported a case of complete remission of recurrent HCC after LT in response to sorafenib treatment. A 50-year-old man underwent LDLT for a huge HCC of 7.4 cm in diameter with PVTT. He developed tumor thrombus in the reconstructed middle hepatic vein and right inferior pulmonary vein and multiple lung metastases at 5 months after LT. However, the recurrent tumors completely resolved on computed tomography after 10 months of sorafenib treatment. To date, he has survived for more than 50 months after LDLT. PVTT is a generally agreed contraindication for LT. Nonetheless, that patient achieved long-term survival by means of LDLT and sorafenib treatment for recurrent HCC.
An expected survival rate of~50% may be acceptable in LDLT, as mentioned earlier. However, the cutoff level of expected survival is not vitally important. LDLT is occasionally performed for cases of far advanced HCC in Korea. In unpublished Korean multicenter data, patients who underwent LDLT for HCC with major vessel invasion accounted for 14.4% (99 patients) of all 688 patients who received transplants for HCC beyond the Milan criteria. In LDLT for HCC, not only the risk of tumor recurrence but also the recipient's chance of survival and the donor's wishes should be considered (31) . Many patients with far advanced HCC have few better treatment options than LT. Even far advanced HCC may not recur if the biology of the tumor is favorable. In addition, combination therapy of with an mTOR inhibitor and sorafenib improves survival even after HCC recurrence. Therefore, LDLT could be considered for far advanced HCC in the following select situations: there are no other effective treatment options, patients are expected to benefit from LT, and the expected survival rate and risks to the donor are fully understood by both the recipient and the donor (31). Even PVTT is not an absolute contraindication for LDLT in Korea.
Conclusion
Based on the idea that the Milan criteria may be overly restrictive and thus exclude a significant number of HCC patients who could benefit from LT, many expanded criteria for HCC have been suggested to date. However, in the setting of DDLT, liberal expansion of the criteria should be restricted because LT for HCC is justified only when the expected results are comparable to those of patients with non-malignant indications. On the other hand, in LDLT, liver grafts are dedicated to only one potential recipient based on an established donor-recipient relationship. Therefore, further expansion of the LT criteria for HCC is possible in LDLT.
Experiences in Korean LT centers show that patients with far advanced HCC may have excellent chances of survival after LT if tumor biology is favorable. Serum AFP level, DCP level and 18 F-FDG PET status could predict post-LT outcomes better than morphological parameters, although no consensus on the application of those biomarkers has yet been established.
In LDLT, the recipient's benefit from LT and the wishes of the donor as well as the risk of recurrence after LT should be considered. In addition, combination therapy with an mTOR inhibitor and sorafenib improves overall survival even after HCC recurrence. Therefore, LDLT should be considered even for far advanced HCC if there are no other effective treatment options and a well-informed donor wishes to provide the only chance of a cure to the recipient.
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